Evidence map›Paper›PMID 32634265›Full record

ArticleMolecular oncology2020

The Sp1/FOXC1/HOTTIP/LATS2/YAP/β-catenin cascade promotes malignant and metastatic progression of osteosarcoma.

Ke Liu, Jiang-Dong Ni, Wen-Zhao Li, Bai-Qi Pan, Yu-Ting Yang, Qin Xia, Jun Huang

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Regulation and Function of FOXC1 in Osteoblasts.Journal of developmental biology · 2023
    Article
  6. Specificity Proteins (Sp) and Cancer.International journal of molecular sciences · 2023
    Review
  7. The role of long non-coding RNA HCG18 in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ke LiuDepartment of Ophthalmology, The 2nd Xiangya Hospital, Central South University, Changsha, China.
Jiang-Dong NiDepartment of Orthopaedics, The 2nd Xiangya Hospital, Central South University, Changsha, China.
Wen-Zhao LiDepartment of Orthopaedics, The 2nd Xiangya Hospital, Central South University, Changsha, China.
Bai-Qi PanDepartment of Orthopaedics, The 2nd Xiangya Hospital, Central South University, Changsha, China.
Yu-Ting YangDepartment of Ophthalmology, The 2nd Xiangya Hospital, Central South University, Changsha, China.
Qin XiaDepartment of Orthopaedics, The 2nd Xiangya Hospital, Central South University, Changsha, China.
Jun HuangDepartment of Orthopaedics, The 2nd Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0002-3735-3200
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis for osteosarcoma (OS) is dismal due to the aggressive tumor growth and high incidence of metastasis. The long noncoding RNA human homeobox A transcript at the distal tip (HOTTIP) and the transcription factor forkhead box C1 (FOXC1) present oncogenic activities in OS. Here, we aimed at gaining insights into the underlying mechanisms and their crosstalk. The expression of FOXC1 and HOTTIP in OS tissues or cell lines was examined by real-time PCR (RT-PCR) and western blot. The in vitro effects of FOXC1 or HOTTIP on cell viability, proliferation, migration, invasion, and expression of target genes were examined using MTT, colony-forming assay, wound-healing, Transwell invasion, and western blot, respectively; the in vivo effects were examined using xenograft and experimental metastasis models. Molecular control of HOTTIP on large tumor suppressor 2 (LATS2) or transactivation of FOXC1 or Sp1 on HOTTIP was assessed by combining RNA immunoprecipitation, qRT-PCR, western blot, ChIP, and luciferase assay. Both FOXC1 and HOTTIP were potently up-regulated in OS tissues and cell lines. FOXC1 and HOTTIP essentially maintained viability, proliferation, migration, and invasion of OS cells in vitro and contributed to xenograft growth or lung metastasis in vivo. Mechanistically, HOTTIP recruited enhancer of zeste homolog 2 (EZH2) and lysine-specific demethylase 1 (LSD1) to silence LATS2 and thus activated YAP/β-catenin signaling. Upstream, Sp1 activated FOXC1 and they both directly transactivated HOTTIP. In summary, we showed that the Sp1/FOXC1/HOTTIP/LATS2/YAP/β-catenin cascade presented oncogenic activities in OS cells. Targeting FOXC1 or HOTTIP may therefore prove beneficial for OS treatment.

Indexed as

Disease ProgressionAdaptor Proteins, Signal TransducingAnimalsBase Sequencebeta CateninCell Line, TumorCell MovementCell ProliferationCell SurvivalEnhancer of Zeste Homolog 2 ProteinForkhead Transcription FactorsGene Expression Regulation, NeoplasticHumansMice, Inbred BALB CMice, NudeModels, BiologicalAdaptor Proteins, Signal Transducingbeta CateninEnhancer of Zeste Homolog 2 ProteinForkhead Transcription FactorsFOXC1 protein, humanLATS2 protein, humanlong noncoding RNA HOTTIP, humanProtein Serine-Threonine KinasesRNA, Long NoncodingSp1 Transcription FactorTranscription FactorsTumor Suppressor ProteinsYAP1 protein, humanYAP-Signaling ProteinsFOXC1HOTTIPLATS2osteosarcomaSp1

Identifiers

PMID32634265
PMCPMC7530777
OpenAlexW3041926928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.